Skip to contentV
Voyager Therapeutics, Inc.
V
VYGRVoyager Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$4.85M$4.85M+581.6% vs Q2 2022 Net Income-$22.21M-$22.21MN/M vs Q2 2022 EPS Diluted-$0.51-$0.51N/M vs Q2 2022 Operating Income-$25,426,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Voyager Therapeutics, Inc. · CIK 1640266 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,045,000N/M Margins · derivedOperating margin-523.9%+2196.2 pt vs Q2 2022
Net margin-457.6%+2223.1 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 3, 2023 · 34 d after period end